Literature DB >> 21225594

Regulation of proliferation and differentiation of human fetal bone cells.

Nathalie Krattinger1, Lee A Applegate, Emmanuel Biver, Dominique P Pioletti, Joseph Caverzasio.   

Abstract

During the last decade, extensive research has been performed in the field of orthopedic medicine to develop cell-based therapies for the restoration of injured bone tissue. We previously demonstrated that human primary fetal bone cells (HFBCs) associated with porous scaffolds induced a bone formation in critical calvaria defect; however, the environmental factors regulating their behavior in culture have not been identified. HFBCs (human fetal femur,12 week development) were compared to marrow-derived human mesenchymal stem cells (HMSCs) for their capacity to proliferate and differentiate into osteoblasts under various culture conditions. When cultured in standard alphaMEM medium, PDGF and FGF-2 increased cell proliferation of both cell types. Investigation of the differentiating capacity of HFBCs and HMSCs in a normal culture medium indicated that HFBCs expressed higher expression levels of RUNX2, OSX, and osteogenic markers compared with HMSCs, while SOX9 was expressed at very low levels in both cells types. However, HMSCs, but not HFBCs enhanced osteoblastic markers in response to osteogenic factors. Surprisingly, BMP-2 with osteogenic factors increased cell numbers and reduced osteoblastic differentiation in HFBCs with the opposite effect seen in HMSCs. Associated with a higher expression of osteoblastic markers, HFBCs produced a higher calcified extra cellular matrix compared with HMSCs. Taken together, data presented in this study suggest that HFBCs have characteristics of osteoprecursor cells that are more advanced in their osteogenesis development compared with mesenchymal stem cells, making fetal cells an interesting biological tool for treatment of skeletal defects and diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21225594     DOI: 10.22203/ecm.v021a04

Source DB:  PubMed          Journal:  Eur Cell Mater        ISSN: 1473-2262            Impact factor:   3.942


  7 in total

1.  Human Bone Progenitor Cells for Clinical Application: What Kind of Immune Reaction Does Fetal Xenograft Tissue Trigger in Immunocompetent Rats?

Authors:  Tanja C Hausherr; Katja Nuss; Eric Thein; Lee A Applegate; Dominique P Pioletti
Journal:  Cell Transplant       Date:  2016-11-21       Impact factor: 4.064

2.  Delivery of platelet-derived growth factor as a chemotactic factor for mesenchymal stem cells by bone-mimetic electrospun scaffolds.

Authors:  Matthew C Phipps; Yuanyuan Xu; Susan L Bellis
Journal:  PLoS One       Date:  2012-07-12       Impact factor: 3.240

3.  Regionally-derived cell populations and skeletal stem cells from human foetal femora exhibit specific osteochondral and multi-lineage differentiation capacity in vitro and ex vivo.

Authors:  David Gothard; Kelvin Cheung; Janos M Kanczler; David I Wilson; Richard O C Oreffo
Journal:  Stem Cell Res Ther       Date:  2015-12-18       Impact factor: 6.832

4.  Effect of temporal onsets of mechanical loading on bone formation inside a tissue engineering scaffold combined with cell therapy.

Authors:  T C Hausherr; K Nuss; E Thein; S Krähenbühl; L A Applegate; D P Pioletti
Journal:  Bone Rep       Date:  2018-04-26

5.  Epigenetic regulation during fetal femur development: DNA methylation matters.

Authors:  María C de Andrés; Emmajayne Kingham; Kei Imagawa; Antonio Gonzalez; Helmtrud I Roach; David I Wilson; Richard O C Oreffo
Journal:  PLoS One       Date:  2013-01-28       Impact factor: 3.240

6.  Gene expression profiles induced by growth factors in in vitro cultured osteoblasts.

Authors:  A Robubi; C Berger; M Schmid; K R Huber; A Engel; W Krugluger
Journal:  Bone Joint Res       Date:  2014-07       Impact factor: 5.853

7.  Holistic Approach of Swiss Fetal Progenitor Cell Banking: Optimizing Safe and Sustainable Substrates for Regenerative Medicine and Biotechnology.

Authors:  Alexis Laurent; Nathalie Hirt-Burri; Corinne Scaletta; Murielle Michetti; Anthony S de Buys Roessingh; Wassim Raffoul; Lee Ann Applegate
Journal:  Front Bioeng Biotechnol       Date:  2020-10-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.